What You Don’t Know About Jeanmarie Guenot, President and C.E.O Amphivena Therapeutics

 

Jeanmarie Guenot holds a Ph.D from the University of California and has an MBA from the University of Pennsylvania. She studied physical and medical chemistry majoring in quantum and semi-empirical methods for drug design, protein structure prediction, X-ray & NMR refinement, and molecular dynamics. Dr. Guenot has more than 20 years of experience in the biotechnology and pharmaceutical industry. She has spent all those hours of experience in the public and private sectors with keen interests in corporate & commercial development, venture capital, pharmaceutical R&D, business development as well as project & alliance management.

Jeanmarie is the incumbent head of the leadership team of Amphivena Therapeutics, Inc., which was founded in 2013 to treat hematologic malignancies. She has an expansive portfolio, project, and alliance management experience in ophthalmic diseases, autoimmune diseases, oncology, neurology, and cardiovascular diseases. Before assuming her current position, Dr. Guenot held many other positions including serving as vice president for Corporate & Business Development at PDL Biopharma, being a business advisor for Hoffmann-La Roche, and founding SKS Ocular, which is a start-up that is an incubator of ophthalmic companies.

 

With the wealth of experience to her name, Jeanmarie Guenot’s contribution to Amphivena Therapeutics is irrefutable. Under her leadership, the company has devised a new method in the treatment of acute myeloid leukemia through the development of a Bispecific Tetravalent CD33/CD3 TandAb. Cytotoxic chemotherapy has largely been used in the treatment of the disease but with the new development, immunotherapeutic can be used as an alternative.

Still under the headship of Jeanmarie Guenot and led by MPM capital the company was able to raise 14 million U.S dollars in a Series A Financing in 2013. Another achievement that stands out is the company’s ability to make the first and second milestones in an agreement it signed with Janssen Biotech Incorporation. The accord, which was facilitated by Johnson and Johnson, aimed at selecting a candidate against an undisclosed tumor antigen.

This would later be used in doing further research on the hematological malignancies. Following the accomplishment, Amphivena Therapeutic received an imbursement from Jansen Biotech Incorporation and this opened a window for further research and development.  Read more about what Jeanmarie Guenot is doing in the fight against cancer, through her partnership with Takeda.  Otherwise you can follow Jeanmarie personally on Facebook.